Behcet’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:36 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Behcet’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-of-apremilast-in-children-with-oral-ulcers-from-behcet-s-disease-or-juvenile-psoriatic-arthritis/ Wed, 29 Apr 2026 15:08:59 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-of-apremilast-in-children-with-oral-ulcers-from-behcet-s-disease-or-juvenile-psoriatic-arthritis/ This study is being conducted to evaluate the long-term safety of apremilast in children and young people. The research focuses on individuals living with Behçet’s disease, a long-term condition that causes inflammation throughout the body, or Juvenile Psoriatic Arthritis, a type of chronic joint inflammation that begins in childhood. In both conditions, the study specifically looks at those experiencing oral ulcers, which are painful sores located inside the mouth.

Participants in this study will take apremilast as an oral medication, which can be provided in the form of a film coated tablet or an oral solution. This is an open-label study, meaning that both the researchers and the participants will know which medication is being used. The study is a long-term extension, meaning it follows individuals who have previously participated in other research studies involving this same medication.

]]> Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tocilizumab-and-adalimumab-for-patients-with-severe-uveitis-in-behcets-disease/ Wed, 29 Apr 2026 15:00:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tocilizumab-and-adalimumab-for-patients-with-severe-uveitis-in-behcets-disease/ This clinical trial is focused on studying the treatment of a condition called severe uveitis in people with Behçet’s disease. Uveitis is an inflammation inside the eye that can lead to vision problems, and Behçet’s disease is a rare disorder that causes blood vessel inflammation throughout the body. The study will compare two treatments: tocilizumab and adalimumab. Tocilizumab is a medication given as an injection under the skin, and it works by blocking a protein in the body that can cause inflammation. Adalimumab is also an injection that helps reduce inflammation by targeting a specific protein involved in the body’s immune response.

The purpose of this study is to assess the benefits of tocilizumab compared to adalimumab in treating sight-threatening uveitis in Behçet’s disease. Participants in the study will receive either tocilizumab or adalimumab and will be monitored over a period of time to see how well the treatments work in reducing eye inflammation and improving vision. The study will also look at how these treatments affect the need for other medications, like corticosteroids, which are often used to control inflammation.

Throughout the study, participants will have regular check-ups to monitor their eye health and overall well-being. The study aims to provide valuable information on the effectiveness and safety of these treatments for people with severe uveitis due to Behçet’s disease. This research could help improve treatment options and outcomes for patients with this challenging condition.

]]> Study on Steroid and Rivaroxaban Treatment for Deep Vein Thrombosis in Behçet’s Syndrome Patients https://clinicaltrials.eu/trial/study-on-steroid-and-rivaroxaban-treatment-for-deep-vein-thrombosis-in-behcets-syndrome-patients/ Wed, 29 Apr 2026 14:57:55 +0000 https://clinicaltrials.eu/trial/study-on-steroid-and-rivaroxaban-treatment-for-deep-vein-thrombosis-in-behcets-syndrome-patients/ This clinical trial is focused on studying the treatment of deep venous thrombosis related to Behçet’s syndrome. Deep venous thrombosis is a condition where blood clots form in the deep veins, often in the legs, which can lead to serious complications. Behçet’s syndrome is a rare disorder that causes blood vessel inflammation throughout the body. The study will compare the effectiveness of using a combination of steroid therapy and anticoagulants versus steroid therapy alone. Steroid therapy involves using medications like prednisone to reduce inflammation, while anticoagulants, such as rivaroxaban, help prevent blood clots.

The purpose of the study is to assess how well the combination of treatments works in reducing the recurrence of deep venous thrombosis without causing major bleeding. Participants will be randomly assigned to receive either the combination of steroid therapy and anticoagulants or steroid therapy alone. The study will last for several months, during which participants will take the medications orally and attend regular check-ups to monitor their health and the effectiveness of the treatment.

Throughout the study, researchers will observe the rate of deep venous thrombosis relapse, any major bleeding events, and the overall health of the participants. They will also look at the quality of life and any changes in the activity of Behçet’s syndrome. The study aims to provide valuable information on the best treatment approach for managing deep venous thrombosis in patients with Behçet’s syndrome.

]]> Study on Apremilast for Treating Oral Ulcers in Children with Behçet’s Disease https://clinicaltrials.eu/trial/study-on-apremilast-for-treating-oral-ulcers-in-children-with-behcets-disease/ Wed, 29 Apr 2026 14:27:03 +0000 https://clinicaltrials.eu/trial/study-on-apremilast-for-treating-oral-ulcers-in-children-with-behcets-disease/ This clinical trial is focused on studying the effects of a medication called Apremilast in children who have active oral ulcers associated with Behçet’s Disease. Behçet’s Disease is a rare condition that causes inflammation of the blood vessels, leading to symptoms like mouth sores, eye inflammation, skin rashes, and genital sores. The purpose of this study is to evaluate how effective and safe Apremilast is for treating these oral ulcers in children aged 2 to less than 18 years.

Participants in the study will be randomly assigned to receive either Apremilast or a placebo. Apremilast is taken orally, either as a film-coated tablet or an oral solution. The study will begin with a phase where neither the participants nor the researchers know who is receiving the actual medication or the placebo. This is followed by a phase where all participants will receive Apremilast. The study will last for up to 52 weeks, with regular check-ups to monitor the number of oral ulcers, any changes in pain levels, and overall health and safety.

The study aims to see if Apremilast can reduce the number of oral ulcers and improve the quality of life for children with Behçet’s Disease. Researchers will also look at other factors, such as any side effects, changes in disease activity, and overall growth and development of the participants. This information will help determine if Apremilast is a suitable treatment option for managing oral ulcers in children with Behçet’s Disease.

]]> Study on Filgotinib for Patients with Refractory Behcet’s Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease https://clinicaltrials.eu/trial/study-on-filgotinib-for-patients-with-refractory-behcets-disease-idiopathic-inflammatory-myopathies-and-igg4-related-disease/ Wed, 29 Apr 2026 14:25:38 +0000 https://clinicaltrials.eu/trial/study-on-filgotinib-for-patients-with-refractory-behcets-disease-idiopathic-inflammatory-myopathies-and-igg4-related-disease/ This clinical trial is focused on studying the effects of a medication called filgotinib on certain rare diseases. The diseases being studied are Idiopathic Inflammatory Myopathies, Behçet’s Disease, and IgG4-related Disease. These are conditions where the immune system mistakenly attacks the body’s own tissues, leading to inflammation and other symptoms. The medication filgotinib is taken in the form of film-coated tablets and is known as a JAK-inhibitor, which means it works by blocking certain enzymes in the body that are involved in the immune response.

The purpose of this study is to see how filgotinib affects the quality of life, disease activity, and safety in patients who have these conditions and have not responded well to other treatments. Participants in the study will receive either filgotinib or a placebo, and their progress will be monitored over a period of time. The study will look at various aspects of the diseases, such as the number of oral ulcers, skin disease severity, and overall disease activity, to determine how well the treatment is working.

Throughout the study, participants will be asked to complete forms and assessments to help researchers understand the impact of the treatment on their symptoms and daily life. The study aims to provide valuable information on the potential benefits and safety of using filgotinib for these rare immune-mediated inflammatory diseases. The results could lead to improved treatment options for patients with these challenging conditions.

]]> Study on the Safety and Effectiveness of Filgotinib for Patients with Refractory Behcet’s Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-filgotinib-for-patients-with-refractory-behcets-disease-idiopathic-inflammatory-myopathies-and-igg4-related-disease/ Wed, 29 Apr 2026 14:24:11 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-filgotinib-for-patients-with-refractory-behcets-disease-idiopathic-inflammatory-myopathies-and-igg4-related-disease/ This clinical trial is focused on studying the effects of a medication called filgotinib on certain rare diseases that involve inflammation caused by the immune system. The diseases being studied are Idiopathic Inflammatory Myopathies, Behçet’s disease, and IgG4-related disease. These conditions are characterized by the body’s immune system mistakenly attacking its own tissues, leading to inflammation and various symptoms. The medication being tested, filgotinib, is a type of drug known as a JAK-inhibitor, which works by blocking specific pathways in the immune system that contribute to inflammation.

The purpose of this study is to examine the safety and effectiveness of filgotinib in patients whose symptoms have not improved with standard treatments. Participants in the study will receive either Jyseleca 100 mg or Jyseleca 200 mg film-coated tablets, which contain the active substance filgotinib. The study will last for a period of up to 26 weeks, during which participants will take the medication orally. Some participants may receive a placebo instead of the active medication. Throughout the study, participants will be monitored to assess how well the medication is working and to check for any side effects.

By participating in this study, researchers hope to gather valuable information about the potential benefits and risks of using filgotinib for treating these rare inflammatory diseases. The findings from this study could help improve treatment options for patients with these conditions in the future.

]]>